Hanyang University signed an MOU for precision therapeutics research and development cooperation with NKCL Bio Group at the ERICA Campus, Ansan City, Gyeonggi-do, on the February 16th. Through the agreement, the two institutions will cooperate on precision therapeutics field information sharing, industry-academic cooperation, R&D business and talent training business vitalization, and course and education program development.

Meanwhile, the NKCL Bio Group is leading the popularization of immune cell therapy, which is next-generation chemotherapy, with a ‘customized immune care platform’, and is commercializing NK cell therapy, which is effective in cancer treatment and immune strengthening.